Skip to main content

etakafusp alfa

Generic: Etakafusp Alfa

etakafusp alfa: 2 clinical trials tracked.

etakafusp alfa evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about etakafusp alfa, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trial Registry Records (2)

Phase 1 Clinical Trial of a Personalized Cancer Immunotherapeutic (PCI) Strategy +/- AB248 (CD8-selective IL-2 Mutein Fusion Protein) in Patients With a New Diagnosis of Triple Negative Breast Cancer Undergoing Neoadjuvant Chemoimmunotherapy

NCT07300475Registry updated 2026-02-13·Phase 1
Not yet recruiting

Primary endpoint: Treatment-emergent adverse events (TEAEs)

InterventionalRandomizedopen30 targetStarted 2026-03Completion 2034-121 site · United StatesWashington University School of Medicine

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758Registry updated 2026-09-25·Phase 1·AMGN
Recruiting

Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

Interventionalopen380 targetStarted 2025-09Completion 2031-0119 sites · South Korea, Turkey (Türkiye), United StatesAmgen